• Adept Technology (Tallahassee, Florida) said that they will be exhibiting at the Orthopedic Design Technology Conference and Exhibition at the Grand Wayne Convention Center in Fort Wayne, Indiana, Oct. 29-31. The event brings together the industry’s leading surgeons, manufacturers and designers in orthopedic device manufacturing. The forum will be a key venue for the exhibition of Adept’s robotics portfolio. Adept provides intelligent robotics systems and services.

• Altea Therapeutics (Atlanta) has achieved sustained and steady basal levels of insulin in patients with type 1 diabetes using a small transdermal patch delivering recombinant human insulin in a cost-effective manner. These results were presented at the SMi 8th Annual Diabetes Conference held in London. Altea Therapeutics has clinically studied the basal insulin transdermal patch in over 90 healthy subjects or people with type 1 diabetes. Results showed transdermal delivery of insulin that achieves therapeutic levels in people with type 1 diabetes equivalent to subcutaneous injections of currently marketed long-acting insulins. Altea Therapeutics is a private specialty pharmaceutical company specializing in pharmaceutical products based on a new class of transdermal patches that deliver therapeutic levels of water-soluble small drugs, proteins and carbohydrates.

• ArthroCare (Austin, Texas) reported the launch of its new Opus TwinLock knotless fixation system — a device that, as part of the company’s AutoCuff system family of products, is designed to provide orthopedic surgeons with a faster process for performing arthroscopic rotator cuff repairs. The TwinLock system is equipped with a tiny (1.8 mm), sharp tip, designed to pierce the cuff for easy maneuverability and optimal implant placement while causing minimal disruption to the cuff tendon. The device’s locking wings provide strong bone hold and are set prior to attaching the tendon to the bone to eliminate implant movement once the repair is complete. ArthroCare makes minimally invasive surgical products.

• LCA-Vision (Cincinnati) reported plans for a nationwide rollout of Advanced Medical Optics’ IntraLase femtosecond technology at its LasikPlus vision centers throughout the U.S. This decision was made by LCA-Vision in conjunction with its medical advisory board following a 6-month review and clinical testing process. LCA-Vision’s medical advisory board is comprised of a panel of LasikPlus surgeons who are recognized as some of the most experienced refractive surgeons in the nation. LCA-Vision first began evaluating the IntraLase technology at four of its LasikPlus vision centers this past April, and expanded the test at additional vision centers over recent months. LCA-Vision makes laser vision correction services under the LasikPlus brand.